S&P Futures
4,222.75 +12.75 (+0.30%) Dow Futures
33,363.00 +103.00 (+0.31%) Nasdaq Futures
13,449.25 +57.25 (+0.43%) Russell 2000 Futures
1,976.40 +6.90 (+0.35%) Crude Oil
91.79 -0.14 (-0.15%) Gold
1,801.90 -11.80 (-0.65%)
Cara Therapeutics, Inc. (CARA)
After hours:
- Zacks
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Cara Therapeutics Reports Second Quarter 2022 Financial Results
– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefalin across multiple disease categories; FDA meeting expected in 2H 2022 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 08, 2022 (GLOBE NEWSWI
- Zacks
Should You Buy Cara Therapeutics (CARA) Ahead of Earnings?
Cara Therapeutics (CARA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
